Menu Search
Equities

PetIQ Inc

39L:STU

PetIQ Inc

Actions
  • Price (EUR)15.50
  • Today's Change0.300 / 1.97%
  • Shares traded0.00
  • 1 Year change+49.04%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segment’s services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.

  • Revenue in USD (TTM)1.10bn
  • Net income in USD2.13m
  • Incorporated2016
  • Employees1.93k
  • Location
    PetIQ IncPetiq Llc, 230 E. Riverside Dr.EAGLE 83616United StatesUSA
  • Phone+1 (208) 939-8900
  • Fax+1 (302) 655-5049
  • Websitehttps://petiq.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.